Chronic treatment of rats with phenobarbital has been reported to decrease gluconeogenesis in rat hepatocytes by a 50 % inhibition of phosphoenolpyruvate (P-pyruvate) carboxykinase activity [Argaud, D., Halimi, S., Catelloni, F. & Leverve, X. (1991) Biochem. J . 280, 663-6691. Contrary to the current knowledge of P-pyruvate carboxykinase regulation, we failed to find a diminution of either P-pyruvate carboxykinase protein (by using a polyclonal antibody) or P-pyruvate carboxykinase mRNA, in the liver of rats treated with phenobarbital for 2 weeks. Kinetic studies of P-pyruvate carboxykinase activity, measured by either carboxylation of P-pyruvate or decarboxylation of oxaloacetate, revealed a decrease in both V,,, and K, after phenobarbital treatment, whereas the nutritional state affected only the V,,,,, as expected. Assessment of P-pyruvate carboxykinase specificity was confirmed by the full inhibition of the enzyme with its specific inhibitor 3-mercaptopicolinate in the micromolar range. P-Pyruvate carboxykinase, purified either by ammonium sulfate fractionation or by immunoprecipitation, exhibited a similar decrease in affinity after phenobarbital treatment. Although the molecular mass does not appear to be altered, the pH sensitivity to 3-mercaptopicolinate inhibition and the enzyme recovery after immunoprecipitation both seemed to be affected. This leads us to propose that the effect of chronic phenobarbital treatment on P-pyruvate carboxykinase activity is not the result of transcriptional regulation but is exerted at the post-translational level.Keywords: P-pyruvate carboxykinase; phenobarbital ; gluconeogenesis ; 3-mercaptopicolinate; rat.Phosphoenolpyruvate (P-pyruvate) carboxykinase, a key regulatory enzyme in gluconeogenesis, adapts readily to the mammal's need for glucose: fasting is an inducer, feeding is a deinducer. Its synthetic rate is controlled by a number of hormones including glucagon, insulin, glucocorticoids, and thyroid hormones. The rapid changes in P-pyruvate carboxykinase synthesis are preceded by similar changes in the abundance of the mRNA coding for the enzyme (Cimbala et al., 1982;Lamers et al., 1982;Beale et al., 1982;Andreone et al., 1982).Phenobarbital, a drug used for the treatment of epileptic patients, has been reported to improve the hyperglycemic state of diabetic patients (Lathela et al., 1985). In the rat, we have previously reported an inhibition of gluconeogenesis in hepatocytes from phenobarbital-treated rats, due to a 50% decrease in Ppyruvate carboxykinase activity (Argaud et al., 1991). Considering the current knowledge on P-pyruvate carboxykinase regulation, we hypothezised that this was due to a diminution of protein synthesis resulting from transcriptional shut off and/or an increase in mRNA degradation. Thus, as is observed during variations in the nutritional state, transcription would be the primary site of action of phenobarbital. Surprisingly, after chronic phenobarbital treatment, our study did not reveal any change in P-pyruvate carboxykinase mRNA or prot...